A basal stem cell signature identifies aggressive prostate cancer phenotypes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 47, 2015, Pages E6544-E6552

  Smith, Bryan A ^a   Sokolov, Artem ^b   Uzunangelov, Vladislav ^b   Baertsch, Robert ^b   Newton, Yulia ^b   Graim, Kiley ^b   Mathis, Colleen ^a   Cheng, Donghui ^a   Stuart, Joshua M ^b   Witte, Owen N ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California Santa Cruz   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basal cell; Neuroendocrine prostate cancer; Prostate cancer; RNA seq; Stem cell signature

Indexed keywords

NOTCH4 RECEPTOR; TRANSCRIPTION FACTOR E2F; WNT7A PROTEIN; LEUKOCYTE ANTIGEN; MYC PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; BASAL CELL; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL SUSPENSION; COMPARATIVE STUDY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RNA SEQUENCE; SMALL CELL CARCINOMA; STEM CELL; UPREGULATION; CYTOLOGY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; MAMMARY GLAND; METABOLISM; METASTASIS; NEUROENDOCRINE TUMOR; PATHOLOGY; PROSTATE TUMOR; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ANTIGENS, CD; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MALE; MAMMARY GLANDS, HUMAN; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; PHENOTYPE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; STEM CELLS; TRANSCRIPTION FACTORS;

EID: 84948168577     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1518007112     Document Type: Article

References (74)

1. Oskarsson T, Batlle E, Massagué J (2014) Metastatic stem cells: Sources, niches, and vital pathways. Cell Stem Cell 14(3):306-321.
2. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559-1564.
3. Vanharanta S, Massagué J (2013) Origins of metastatic traits. Cancer Cell 24(4): 410-421.
4. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730-737.
5. Chen J, et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488(7412):522-526.
6. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704-715.
7. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C (2012) Defining the mode of tumour growth by clonal analysis. Nature 488(7412):527-530.
8. Hermann PC, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3): 313-323.
9. Santagata S, Ligon KL, Hornick JL (2007) Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol 31(6):836-845.
10. Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 108(52): 21276-21281.
11. Shats I, et al. (2011) Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 71(5):1772-1780.
12. Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a deathfrom-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115(6):1503-1521.
13. Dieter SM, et al. (2011) Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9(4):357-365.
14. Merlos-Suárez A, et al. (2011) The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8(5):511-524.
15. Pece S, et al. (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1):62-73.
16. Baccelli I, et al. (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539-544.
17. Eppert K, et al. (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17(9):1086-1093.
18. Robinson D, et al. (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215-1228.
19. Karhadkar SS, et al. (2004) Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431(7009):707-712.
20. Acevedo VD, et al. (2007) Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 12(6): 559-571.
21. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ (2011) Wnt/?-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 30(16): 1868-1879.
22. Stoyanova T, et al. (2013) Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci USA 110(50): 20111-20116.
23. Terry S, Beltran H (2014) The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 4(60):60.
24. Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA (2014) Small cell carcinoma of the prostate. Nat Rev Urol 11(4):213-219.
25. Beltran H, et al. (2011) Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1(6):487-495.
26. Goldstein AS, et al. (2008) Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 105(52): 20882-20887.
27. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON (2010) Identification of a cell of origin for human prostate cancer. Science 329(5991):568-571.
28. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE (2010) The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 70(3):333-340.
29. Sørensen KD, et al. (2013) Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer. Br J Cancer 108(2):420-428.
30. Rodríguez JC, et al. (2000) Apolipoprotein D expression in benign and malignant prostate tissues. Int J Surg Investig 2(4):319-326.
31. Begley LA, et al. (2008) CXCL5 promotes prostate cancer progression. Neoplasia 10(3): 244-254.
32. Chai H, Brown RE (2009) Field effect in cancer-An update. Ann Clin Lab Sci 39(4): 331-337.
33. Yu YP, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22(14):2790-2799.
34. Cooper CS, et al.; ICGC Prostate Group (2015) Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 47(4):367-372.
35. Risk MC, et al. (2010) Differential gene expression in benign prostate epithelium of men with and without prostate cancer: Evidence for a prostate cancer field effect. Clin Cancer Res 16(22):5414-5423.
36. Seyednasrollah F, Laiho A, Elo LL (2015) Comparison of software packages for detecting differential expression in RNA-seq studies. Brief Bioinform 16(1):59-70.
37. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
38. Friedman J, Hastie T, Tibshirani R (2010) Regularization paths for generalized linear models via coordinate descent. J Stat Softw 33(1):1-22.
39. Tarca AL, et al. (2009) A novel signaling pathway impact analysis. Bioinformatics 25(1):75-82.
40. Carro MS, et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463(7279):318-325.
41. Aytes A, et al. (2014) Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25(5):638-651.
42. Lefebvre C, et al. (2010) A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol Syst Biol 6(377):377.
43. Cancer Genome Atlas Research Network (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3):676-690.
44. Poon H, Quirk C, DeZiel C, Heckerman D (2014) Literome: PubMed-scale genomic knowledge base in the cloud. Bioinformatics 30(19):2840-2842.
45. Khurana E, Fu Y, Chen J, Gerstein M (2013) Interpretation of genomic variants using a unified biological network approach. PLOS Comput Biol 9(3):e1002886.
46. Lachmann A, et al. (2010) ChEA: Transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26(19):2438-2444.
47. Forrest MP, Waite AJ, Martin-Rendon E, Blake DJ (2013) Knockdown of human TCF4 affects multiple signaling pathways involved in cell survival, epithelial to mesenchymal transition and neuronal differentiation. PLoS One 8(8):e73169.
48. Flora A, Garcia JJ, Thaller C, Zoghbi HY (2007) The E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitors. Proc Natl Acad Sci USA 104(39):15382-15387.
49. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ (2011) Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 71(1):18-25.
50. Yu X, et al. (2014) SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer Prostatic Dis 17(4):301-309.
51. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
52. Badve S, et al. (2007) FOXA1 expression in breast cancer-Correlation with luminal subtype A and survival. Clin Cancer Res 13(15 Pt 1):4415-4421.
53. Bernardo GM, et al. (2013) FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 32(5):554-563.
54. Ben-Porath I, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40(5):499-507.
55. Creighton CJ, et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33): 13820-13825.
56. Lim E, et al.; kConFab (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8): 907-913.
57. Kim J, et al. (2010) A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143(2):313-324.
58. Wong DJ, et al. (2008) Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2(4):333-344.
59. Karthaus WR, et al. (2014) Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159(1):163-175.
60. Taylor BS, et al. (2010) Integrative genomsic profiling of human prostate cancer. Cancer Cell 18(1):11-22.
61. Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57.
62. Rudin CM, et al. (2012) Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44(10):1111-1116.
63. Park KS, et al. (2011) A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 17(11):1504-1508.
64. Coe BP, et al. (2013) Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. PLoS One 8(8):e71670.
65. Bracken AP, et al. (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22(20):5323-5335.
66. Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6(11):846-856.
67. Kareta MS, et al. (2015) Inhibition of pluripotency networks by the Rb tumor suppressor restricts reprogramming and tumorigenesis. Cell Stem Cell 16(1):39-50.
68. Sequist LV, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26.
69. Cheng L, et al. (2005) Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 166(5):1533-1539.
70. Williamson SR, et al. (2011) ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: Evidence supporting monoclonal origin. Mod Pathol 24(8):1120-1127.
71. Shen R, et al. (1997) Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol 3(2): 67-75.
72. Smith GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3(1):Article 3.
73. Ritchie ME, et al. (2015) limma powers differential expression analyses for RNAsequencing and microarray studies. Nucleic Acids Res 43(7):e47.
74. Sales G, Calura E, Martini P, Romualdi C (2013) Graphite Web: Web tool for gene set analysis exploiting pathway topology. Nucleic Acids Res 41(Web Server Issue, W1): W89-W97.